Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference

HALIFAX, NOVA SCOTIA--(Marketwired - April 28, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time.

The presentation will be available on Immunovaccine's website at www.imvaccine.com following the presentation.

This year marks Bloom Burton & Co.'s fifth annual Healthcare Investor Conference. It brings together Canadian, U.S. and international investors who are interested in the latest developments in the Canadian healthcare sector. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in one-on-one meetings with company management.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). In collaboration with commercial and academic partners, Immunovaccine is also expanding the application of DepoVax™ as an adjuvanting platform for vaccines targeted against infectious diseases. Immunovaccine's goal in infectious diseases is to out-license its DepoVax™ platform to partners to generate earlier revenues. For more information, visit www.imvaccine.com.

Immunovaccine Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.